As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 26, 2014
by Diabetes In Control:
There have been concerns and correlations seen with diabetes and risk of developing Alzheimer’s disease or any form of dementia in the future. Any novel strategies to help delay or reduce the risk of dementia can be very beneficial to diabetic patients once they reach a certain point in their life. Alzheimer’s disease can be very detrimental to a patient’s health as well as their personal life.
A study was conducted in Germany starting year 2004 until 2010. German researchers followed 146,000 patients from the age of 60 and older with free of any dementia type diagnosis. They discovered out of 146,000 patients, 13,841 of them developed dementia and the ones who were prescribed an anti diabetic agent called pioglitazone, their risk of developing dementia significantly decreased.
Based on the study, they found a reduced risk of dementia with each additional three months the patient is on pioglitazone. According to Anne Fink, a researcher who helped with the trial, hypothesized that a reduction of inflammation in the brain and nervous system occurs when on pioglitazone long term.
Inflammation of the brain and nervous system has been thought to be the cause of Alzheimer’s disease and by reducing that process can prevent or delay the development of that type of dementia. The study also found that patient’s who are on pioglitazone long term has approximately 20% reduced risk of Alzheimer’s than patients who are solely on insulin.
A five year study by Takeda is currently in the process to determine whether low doses of pioglitazone to detain the mild symptoms of cognitive impairment that is caused by Alzheimer disease. The study consist of patients with normal cognitive function initially and followed up throughout the study to see if the outcome (Alzheimer’s disease) is present or not.
One con of the current study done by Takeda is that the results may not be applicable to the whole population of people with diabetes, because individuals included in the study are the ones with genetic variations that are known to increase the risk of developing dementia. Therefore, outcomes of the study may only pertain to a specific subpopulation of the people with diabetes. Further studies are needed to accurately determine whether pioglitazone can benefit every diabetic patients in reducing the risk of developing Alzheimer’s disease.
White women whose genes put them at risk of developing Alzheimer’s disease are more likely than white men with similar risk genes to be diagnosed between the ages of 65 and 75, a study drawing on...
Researchers at the Keck School of Medicine of USC are tackling the sixth-leading cause of death in the United States—Alzheimer’s disease—with a new study that intervenes decades before the disease develops. The school is...
A devastating chronic neurodegenerative disease, Alzheimer’s disease (AD) currently affects around 5.5 million people in the United States alone. Causing progressive mental deterioration, it ultimately advances to impact basic bodily functions such as walking and...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.